Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Insulet Corporation - Common Stock (NQ: PODD )

280.56 -1.56 (-0.55%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Looking for growth without the hefty price tag? Consider NASDAQ:PODD.
Based on Fundamental Analysis it can be said that NASDAQ:PODD is a growth stock which is not overvalued. 
Via Chartmill
$1000 Invested In Insulet 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Why NASDAQ:PODD Is a Standout High-Growth Stock in a Consolidation Phase.
Based on a technical and fundamental analysis of NASDAQ:PODD we ask: Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
NASDAQ:PODD—A High-Growth Stock Gearing Up for Its Next Upward Move.
Is INSULET CORP (NASDAQ:PODD) on the Verge of a Major Breakout as a Strong Growth Stock? 
Via Chartmill
Insulet Launches Revolutionary Omnipod® 5 in Five More Countries in Europe
From Insulet Corporation
Via Business Wire
If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today
Via Benzinga
Looking Into Insulet's Recent Short Interest
Via Benzinga
Exploring the Growth Potential of NASDAQ:PODD as It Nears a Breakout.
Why INSULET CORP (NASDAQ:PODD) Is a Promising High-Growth Stock in the Midst of Consolidation. 
Via Chartmill
Stryker Had A Good Year Last Year; Here's How It's Looking For 2025
Reflecting its strong growth, on Monday the Relative Strength (RS) Rating for Stryker stock got an upgrade from 70 to 74. 
Via Investor's Business Daily
Insulet to Announce Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From Insulet Corporation
Via Business Wire
Lantheus Stock Doubled In A Year Amid Wide Use Of Its AI-Enabled Medical Devices
Lantheus Holdings sees its Relative Strength Rating reach the 80-plus level. 
Via Investor's Business Daily
Here's How Much $1000 Invested In Insulet 15 Years Ago Would Be Worth Today
Via Benzinga
Inari Medical Stock Gets RS Rating Upgrade
On Wednesday, Inari Medical stock received an upgrade to its Relative Strength (RS) Rating, from 65 to 72. 
Via Investor's Business Daily
Decoding 11 Analyst Evaluations For Insulet
Via Benzinga
Novocure Stock Earns 96 RS Rating
On Tuesday, Novocure stock got a positive adjustment to its Relative Strength (RS) Rating to 96, up from 73. 
Via Investor's Business Daily
Peering Into Insulet's Recent Short Interest
Via Benzinga
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
From Insulet Corporation
Via Business Wire
NASDAQ:PODD qualifies as a high growth stock and is consolidating.
INSULET CORP (NASDAQ:PODD)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott’s FreeStyle Libre 2 Plus Sensor in the U.S.
From Insulet Corporation
Via Business Wire
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
9 Analysts Have This To Say About Insulet
Via Benzinga
Why NASDAQ:PODD qualifies as a high growth stock.
Is INSULET CORP (NASDAQ:PODD) suited for high growth investing? 
Via Chartmill
Top 4 Health Care Stocks That May Plunge This Quarter
Via Benzinga
S&P 500 Breaks 6,000 Points, Dow Soars Above 44,000, Small Caps Eye Strongest Week In 4 Years, Tesla Hits $1 Trillion: What's Driving Markets Friday?
The S&P 500 index surged past the 6,000-point milestone, setting fresh record highs, and small-cap stocks are poised for their best weekly performance since April 2024 as investor optimism surrounding... 
Via Benzinga
Topics Stocks
Exposures US Equities
Insulet Soars Out Of Buy Zone As 'Beat-And-Raise Cadence' Continues
Shares soared out of a buy zone after beating third-quarter forecasts and raising its outlook for 2024. 
Via Investor's Business Daily
High growth, ROE and relative strength for NASDAQ:PODD, growth investors may appreciate this.
Evaluating INSULET CORP (NASDAQ:PODD) for Growth Investment Opportunities. 
Via Chartmill
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
From Insulet Corporation
Via Business Wire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
From Insulet Corporation 
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.